Bio-Rad Laboratories, Inc.Class A

XNYSHealth care

Last traded price · USD

$368.37

−3.06%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:43 IST · A quote does not mean the product is available to trade on your account.

Day's open: $367.29
Previous close: $379.99
Volume: 48,434
Day's high: $372.49
Day's low: $352.09

In brief

Bio-Rad Laboratories, Inc.Class A is a health care company listed on the New York Stock Exchange, valued at about $9.85B.
Its shares closed at $379.99 on 4 Nov 2026, up 22.2% over the past year.
From India you can buy BIO in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Bio-Rad Laboratories, Inc.Class A (BIO) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole BIO share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade BIO options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

4.1% below its 52-week high
Closed at $379.99 on 4 Nov 2026: 4.1% below the 52-week high of $396.23 (27 Aug 2026) and 60.5% above the low of $236.73 (13 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +3.0% (SPY −1.6%, XLV +13.5%). 3 months: +9.2% (SPY −0.4%, XLV +15.5%). 1 year: +22.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BIO, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $379.99 was 1.6% above its 50-day average ($374.18) and 20.9% above its 200-day average ($314.27). It has closed above the 200-day for 84 sessions, since 9 Jul 2026. The 50-day average crossed above the 200-day on 28 Jul 2026, 70 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 5.1% of shares outstanding
1.1M shares were sold short at the 15 Oct 2026 settlement, 5.1% of the 21.7M shares outstanding; covering them would take 4.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+3.0%

6 months+46.7%

1 year+22.2%

5 years−51.5%

Newswire

About

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Website

Notable moves

May 18, 2026
+13.85%
August 1, 2025
+17.63%
May 5, 2023
−16.72%

Newswire

About

Website

Notable moves

May 18, 2026
+13.85%
August 1, 2025
+17.63%
May 5, 2023
−16.72%

Bio-Rad Laboratories, Inc.Class A

XNYSHealth care

Last traded price · USD

$368.37

−3.06%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:43 IST · A quote does not mean the product is available to trade on your account.

Day's open: $367.29
Previous close: $379.99
Volume: 48,434
Day's high: $372.49
Day's low: $352.09

In brief

Bio-Rad Laboratories, Inc.Class A is a health care company listed on the New York Stock Exchange, valued at about $9.85B.
Its shares closed at $379.99 on 4 Nov 2026, up 22.2% over the past year.
From India you can buy BIO in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Bio-Rad Laboratories, Inc.Class A (BIO) shares from India?

Do I need the price of a whole BIO share to invest?

How much can I invest in US stocks in a year?

Can I trade BIO options or futures?

Insights

Quotes run fifteen minutes behind.

4.1% below its 52-week high
Closed at $379.99 on 4 Nov 2026: 4.1% below the 52-week high of $396.23 (27 Aug 2026) and 60.5% above the low of $236.73 (13 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +3.0% (SPY −1.6%, XLV +13.5%). 3 months: +9.2% (SPY −0.4%, XLV +15.5%). 1 year: +22.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BIO, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $379.99 was 1.6% above its 50-day average ($374.18) and 20.9% above its 200-day average ($314.27). It has closed above the 200-day for 84 sessions, since 9 Jul 2026. The 50-day average crossed above the 200-day on 28 Jul 2026, 70 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 5.1% of shares outstanding
1.1M shares were sold short at the 15 Oct 2026 settlement, 5.1% of the 21.7M shares outstanding; covering them would take 4.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+3.0%

6 months+46.7%

1 year+22.2%

5 years−51.5%

Newswire

About

Website

Notable moves

May 18, 2026
+13.85%
August 1, 2025
+17.63%
May 5, 2023
−16.72%

Newswire

About

Website

Notable moves

May 18, 2026
+13.85%
August 1, 2025
+17.63%
May 5, 2023
−16.72%

Bio-Rad Laboratories, Inc.Class A

Bio-Rad Laboratories, Inc.Class A in brief

4.1% below its 52-week high

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

Short interest at 5.1% of shares outstanding

Bio-Rad Laboratories, Inc.Class A

Bio-Rad Laboratories, Inc.Class A in brief

4.1% below its 52-week high

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

Short interest at 5.1% of shares outstanding